Pharmaceuticals

Avastin (Bevacizumab) Market 2026 expanding with oncology biosimilar adoption

March 25, 2026March 25, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Avastin (Bevacizumab) Market Projected To Become By 2030 Based On Its 2026 Valuation?

The avastin (bevacizumab) market size has demonstrated significant expansion in recent years. Its value is expected to rise from $7.82 million in 2025 to $8.43 million by 2026, achieving a compound annual growth rate (CAGR) of 7.8%. This historical growth can be credited to the clinical affirmation of VEGF inhibition, the escalating global prevalence of cancer, extensive label expansion approvals, high recognition among oncologists, and its initial application in colorectal cancer treatment.

The avastin (bevacizumab) market is anticipated to experience substantial growth in the upcoming years, expanding to $11.27 million by 2030, at a compound annual growth rate (CAGR) of 7.5%. This growth during the forecast period is propelled by factors including the emergence of bevacizumab biosimilars, an expanding patient population in oncology, increased utilization in developing markets, the demand for cost-effective biologics, and optimized combination treatment regimens. Significant trends for the forecast period encompass the ongoing application of anti-angiogenic cancer therapies, the broadening use of avastin across diverse cancer types, an increase in combination therapy with chemotherapy, growing adoption in ophthalmic indications, and a heightened focus on biosimilar competition.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19879&type=smp

What Primary Drivers Are Shaping The Development Of The Avastin (Bevacizumab) Market?

The expansion of the avastin (bevacizumab) market is poised to be driven by the escalating prevalence of cancer. Cancer, a collective term for conditions characterized by the uncontrolled proliferation and dissemination of aberrant cells throughout the body, is witnessing increased occurrence owing to an aging demographic, evolving lifestyle habits, and enhanced diagnostic methods. Avastin combats cancer by inhibiting VEGF, thus obstructing the development of blood vessels that supply oxygen and nutrients to tumors, effectively starving them. As an illustration, in August 2024, Macmillan Cancer Support, a UK-based organization, reported that over 3 million people in the UK lived with cancer in 2024, with projections indicating an increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Hence, the rising incidence of cancer is a key stimulant for the avastin (bevacizumab) market’s growth.

Avastin (Bevacizumab) Market Driver: Impact Of Rising Healthcare Expenditure On Avastin (Bevacizumab) Market Growth

The avastin (bevacizumab) market is projected to grow as healthcare expenditure continues to climb. Healthcare expenditure represents the total funds allocated to health-related goods and services, including personal care, preventive strategies, and public health programs aimed at improving health within a specific period. This rise in spending is attributed to an aging population, the prevalence of chronic diseases, advancements in medical technology, high pharmaceutical costs, inefficient payment systems, and increased demand for services. Greater healthcare expenditure benefits avastin (bevacizumab) by enhancing patient access through insurance coverage, thus supporting its market expansion and wider adoption. For example, in May 2024, the Office for National Statistics, a UK-based government agency, reported that total healthcare expenditure in nominal terms surged by 5.6% from 2022 to 2023, which is considerably higher than the 0.9% growth rate recorded in 2022. Therefore, increased healthcare spending is a key driver for the avastin (bevacizumab) market.

What Segment Groups Are Identified Within The Avastin (Bevacizumab) Market?

The avastin (bevacizumab) market covered in this report is segmented –

1) By Dosage: 100 Mg, 400 Mg

2) By Application: Non Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, Cervical Cancer, Colorectal Cell Cancer, Ovarian Cancer, Proliferative Diabetic Retinopathy, Malignant Glioma, Neurofibromatosis, Pancreatic Cancer, Other Applications

3) By Distribution channel: Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

4) By End User: Hospitals, Cancer Supportive Centers, Home Healthcare, Academic And Research Institutes, Other End Users

What Trends Are Advancing Progress In The Avastin (Bevacizumab) Market?

Leading companies in the Avastin (bevacizumab) market are concentrating on the expansion of biosimilars, including significant bevacizumab biosimilars, to achieve a competitive advantage. Biosimilar proliferation denotes the rapid growth in the availability and number of biosimilar medications in the market. As an illustration, in December 2023, Bio Thera Solutions, a biopharmaceutical company based in China, secured FDA approval for Avzivi (bevacizumab tnjn), an Avastin biosimilar, which exhibits equivalent efficacy, safety, and immunogenicity to the reference product. In July 2024, the European Medicines Agency (EMA) similarly approved BAT1706 / Avzivi for various oncology indications. These progressions are fostering increased affordability and patient access. Conversely, they also amplify pricing pressure on the originator drug, contest market share, and require substantial manufacturing capacity from new market participants.

Which Companies Hold Significant Positions In The Avastin (Bevacizumab) Market?

Major companies operating in the avastin (bevacizumab) market are Roche Holding AG

Read the full avastin (bevacizumab) market report here:

https://www.thebusinessresearchcompany.com/report/avastin-bevacizumab-global-market-report

How Does The Avastin (Bevacizumab) Market Perform Across Major Global Regions?

North America was the largest region in the avastin (bevacizumab) market in 2025. The regions covered in the avastin (bevacizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Avastin (Bevacizumab) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19879&type=smp

Browse Through More Reports Similar to the Global Avastin (Bevacizumab) Market 2026, By The Business Research Company

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Adalimumab Infliximab And Etanercept Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-market

Antiviral Combination Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795